About Oxygen Biotherapeutics (NASDAQ:TENX)
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TENX
CUSIPN/A
Phone919-855-2100
Debt
Debt-to-Equity RatioN/A
Current Ratio8.06%
Quick Ratio8.06%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$40,000.00
Price / Sales229.46
Cash FlowN/A
Price / CashN/A
Book Value$6.29 per share
Price / Book1.01
Profitability
EPS (Most Recent Fiscal Year)($13.20)
Net Income$-8,830,000.00
Net MarginsN/A
Return on Equity-79.53%
Return on Assets-66.04%
Miscellaneous
Employees8
Outstanding Shares1,450,000
Oxygen Biotherapeutics (NASDAQ:TENX) Frequently Asked Questions
What is Oxygen Biotherapeutics' stock symbol?
Oxygen Biotherapeutics trades on the NASDAQ under the ticker symbol "TENX."
When did Oxygen Biotherapeutics' stock split? How did Oxygen Biotherapeutics' stock split work?
Shares of Oxygen Biotherapeutics reverse split on Monday, February 26th 2018. The 1-20 reverse split was announced on Friday, February 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 23rd 2018. An investor that had 100 shares of Oxygen Biotherapeutics stock prior to the reverse split would have 5 shares after the split.
How were Oxygen Biotherapeutics' earnings last quarter?
Oxygen Biotherapeutics (NASDAQ:TENX) released its quarterly earnings data on Tuesday, December, 15th. The specialty pharmaceutical company reported ($2.60) EPS for the quarter, beating the Zacks' consensus estimate of ($2.80) by $0.20. View Oxygen Biotherapeutics' Earnings History.
What price target have analysts set for TENX?
1 brokers have issued 1-year price objectives for Oxygen Biotherapeutics' shares. Their forecasts range from $50.00 to $50.00. On average, they anticipate Oxygen Biotherapeutics' stock price to reach $50.00 in the next twelve months. View Analyst Ratings for Oxygen Biotherapeutics.
Who are some of Oxygen Biotherapeutics' key competitors?
Who are Oxygen Biotherapeutics' key executives?
Oxygen Biotherapeutics' management team includes the folowing people:
- Mr. Michael B. Jebsen, Interim CEO, Pres & CFO (Age 47)
- Mr. John P. Kelley, Consultant (Age 64)
- Ms. Nancy J. M. Hecox, Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.
- Maria Isabel Tomargo, Assistant VP of Marketing & Sales
- Mr. Robert F. Diegelmann Ph.D., Head of New Wound Care Division
Has Oxygen Biotherapeutics been receiving favorable news coverage?
Media stories about TENX stock have been trending positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oxygen Biotherapeutics earned a news impact score of 0.46 on Accern's scale. They also assigned media coverage about the specialty pharmaceutical company an impact score of 45.01 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Oxygen Biotherapeutics?
Shares of TENX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oxygen Biotherapeutics' stock price today?
One share of TENX stock can currently be purchased for approximately $6.33.
How big of a company is Oxygen Biotherapeutics?
Oxygen Biotherapeutics has a market capitalization of $9.48 million and generates $40,000.00 in revenue each year. The specialty pharmaceutical company earns $-8,830,000.00 in net income (profit) each year or ($13.20) on an earnings per share basis. Oxygen Biotherapeutics employs 8 workers across the globe.
How can I contact Oxygen Biotherapeutics?
Oxygen Biotherapeutics' mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The specialty pharmaceutical company can be reached via phone at 919-855-2100 or via email at [email protected]
MarketBeat Community Rating for Oxygen Biotherapeutics (TENX)
MarketBeat's community ratings are surveys of what our community members think about Oxygen Biotherapeutics and other stocks. Vote "Outperform" if you believe TENX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TENX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Oxygen Biotherapeutics (NASDAQ:TENX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Oxygen Biotherapeutics in the last 12 months. Their average twelve-month price target is $50.00, suggesting that the stock has a possible upside of 689.89%. The high price target for TENX is $50.00 and the low price target for TENX is $50.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $50.00 | $50.00 | $50.00 | $50.00 |
| Price Target Upside: | 689.89% upside | 409.68% upside | 409.68% upside | 409.68% upside |
Oxygen Biotherapeutics (NASDAQ:TENX) Consensus Price Target History
Oxygen Biotherapeutics (NASDAQ:TENX) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/18/2017 | Ladenburg Thalmann | Upgrade | Neutral -> Buy | $50.00 | High |  |
(Data available from 4/26/2016 forward)
Oxygen Biotherapeutics (NASDAQ:TENX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Oxygen Biotherapeutics (NASDAQ TENX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.92%
Oxygen Biotherapeutics (NASDAQ TENX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/18/2017 | Ronald R Blanck | Director | Buy | 12,950 | $0.45 | $5,827.50 | 13,624 | |
| 11/14/2017 | Ronald R Blanck | Director | Sell | 12,950 | $0.39 | $5,050.50 | 7,149 | |
| 11/23/2016 | Gerald T Proehl | Director | Buy | 29,882 | $1.67 | $49,902.94 | 15,433 | |
| 11/19/2015 | Ronald R Blanck | Director | Buy | 4,700 | $3.26 | $15,322.00 | 12,899 | |
| 1/20/2015 | Ronald R Blanck | Director | Buy | 2,000 | $3.49 | $6,980.00 | | |
(Data available from 1/1/2013 forward)
Oxygen Biotherapeutics (NASDAQ TENX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | How Do Analysts See Tenax Therapeutics Inc (NASDAQ:TENX) Performing In The Next Couple Of Years?
finance.yahoo.com - April 13 at 4:38 PM |
| TENX: New Indication for Levosimendan
finance.yahoo.com - April 12 at 10:06 AM |
 | Analysts Issue Forecasts for Oxygen Biotherapeutics' FY2018 Earnings (TENX)
www.americanbankingnews.com - April 11 at 8:55 AM |
| Analysts Offer Predictions for Oxygen Biotherapeutics' Q1 2018 Earnings (TENX)
www.americanbankingnews.com - April 10 at 6:30 AM |
| Finding Breakouts And Avoiding Fakeouts In A Market At War With Itself
finance.yahoo.com - April 6 at 4:50 PM |
| Benzinga's Top Analyst Calls From April 5, 2018
finance.yahoo.com - April 6 at 9:38 AM |
| Amid strategic review, Tenax gets go-ahead from FDA
finance.yahoo.com - April 6 at 9:38 AM |
 | Tenax advancing development of pulmonary hypertension candidate levosimendan; shares up 11% premarket
seekingalpha.com - April 4 at 4:52 PM |
 | Tenax Therapeutics (TENX) Announces Results of Pre-IND Meeting with FDA for Phase 2 Study of Levosimendan in PH-HFpEF Patients
www.streetinsider.com - April 4 at 4:52 PM |
| Tenax Therapeutics Announces Results of Pre-IND Meeting with FDA for Phase 2 Study of Levosimendan in PH-HFpEF Patients
finance.yahoo.com - April 4 at 4:52 PM |
| Tenax Therapeutics Inc’s (NASDAQ:TENX) Shift From Loss To Profit
finance.yahoo.com - April 4 at 4:52 PM |
| Tenax Therapeutics (TENX) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - March 25 at 12:51 AM |
| Tenax Therapeutics (TENX) Reports Compliance with Nasdaq Minimum Bid Price Requirement - StreetInsider.com
www.streetinsider.com - March 16 at 9:33 AM |
| Tenax Therapeutics (TENX) Reports Compliance with Nasdaq Minimum Bid Price Requirement
www.streetinsider.com - March 14 at 10:13 AM |
| Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
finance.yahoo.com - March 14 at 10:13 AM |
| With A -97.88% Earnings Drop Lately, Did Tenax Therapeutics Inc (NASDAQ:TENX) Underperform Its Industry?
finance.yahoo.com - March 8 at 5:34 PM |
| Tenax Therapeutics Announces New Scientific Publication of Preclinical Data Provides Additional Evidence of Levosimendan Treatment Effects in Pulmonary Hypertension
finance.yahoo.com - March 1 at 9:01 AM |
| Tenax Therapeutics Announces Reverse Stock Split
finance.yahoo.com - February 23 at 9:12 AM |
| World-Recognized Experts Join Tenax Therapeutics’ Scientific Advisory Board to Guide New Phase 2 Study
finance.yahoo.com - February 6 at 9:15 AM |
| ValuEngine Upgrades Tenax Therapeutics (TENX) to "Sell"
www.americanbankingnews.com - February 4 at 11:54 AM |
| Tenax Therapeutics (TENX) to Develop Levosimendan for Pulmonary Hypertension Indication
www.streetinsider.com - January 17 at 11:15 AM |
| Tenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmonary Hypertension Indication with No FDA Approved Therapies
finance.yahoo.com - January 16 at 11:24 AM |
| Does Zero-Debt Make Tenax Therapeutics Inc (NASDAQ:TENX) A Financially Strong Company?
finance.yahoo.com - January 2 at 9:03 PM |
 | How These Biotech Stocks are Performing? -- Agenus, Aptose Biosciences, RXi Pharma, and Tenax Therapeutics
www.bizjournals.com - August 4 at 8:54 AM |
| TENX: FDA Response on Levosimendan
finance.yahoo.com - August 3 at 7:52 AM |
| Tenax Therapeutics Provides Regulatory Update on Levosimendan
finance.yahoo.com - July 29 at 7:50 AM |
| Tenax Therapeutics (TENX) Reviews Additional Data with FDA & Potential Levosimendan NDA Submission
www.streetinsider.com - May 16 at 8:10 PM |
| Tenax Therapeutics (TENX) to Review Strategic Alternatives; CEO Resigns
www.streetinsider.com - April 7 at 11:21 PM |
| Tenax Therapeutics (TENX) to Review Strategic Alternatives; CEO Resigns - StreetInsider.com
www.streetinsider.com - April 7 at 12:58 PM |
| Tenax Therapeutics (TENX) Offers FY16 Results, Corporate Update
www.streetinsider.com - March 22 at 12:57 AM |
 | BUZZ-US STOCKS ON THE MOVE-Banks, Chipotle, Airlines, Pain Therapeutics, Pulmatrix, Sunshine Heart - Nasdaq
www.nasdaq.com - March 21 at 7:54 PM |
| Tenax Therapeutics (TENX) Offers FY16 Results, Corporate Update - StreetInsider.com
www.streetinsider.com - March 21 at 7:54 PM |
| Q4 2016 Tenax Therapeutics Inc Earnings Release - Before Market Open
biz.yahoo.com - March 21 at 9:57 AM |
| TENAX THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St
biz.yahoo.com - March 17 at 8:13 PM |
| TENAX THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 9:13 PM |
 | Tenax Therapeutics Inc. (TENX) Plummeted To A New Low On Study Results - RTT News
www.rttnews.com - February 3 at 6:11 AM |
| Tenax Therapeutics Inc. (TENX) Has Plunged To A New Low On Phase 3 Study News
www.rttnews.com - February 2 at 5:55 AM |
 | 9:00 am Tenax Therapeutics announces top-line results from its Phase 3 LEVO-CTS trial; study did not achieve statistically significant reductions in dual or quad primary endpoints (shares halted)
us.rd.yahoo.com - February 2 at 5:55 AM |
| Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery
us.rd.yahoo.com - February 2 at 5:55 AM |
| Tenax Therapeutics (TENX) Says Phase 3 LEVO-CTS Trial in Cardiac Surgery Did Not Achieve Dual Endpoint - StreetInsider.com
www.streetinsider.com - February 1 at 6:52 AM |
| Tenax Therapeutics: Will It Or Won't It?
www.rttnews.com - January 30 at 11:29 AM |
Oxygen Biotherapeutics (NASDAQ:TENX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Oxygen Biotherapeutics (NASDAQ:TENX) Income Statement, Balance Sheet and Cash Flow Statement
Oxygen Biotherapeutics (NASDAQ TENX) Stock Chart for Thursday, April, 26, 2018
Loading chart…
